Intravesical AD 32 (Valrubicin) in Patients With Carcinoma in Situ (CIS) of the Bladder Who Have Failed or Have Recurrence Following Treatment With Bacillus Calmette-guerin (BCG)

Stacy Childs, MD, Alabaster

William Bohnert, MD, Phoenix

Scott Swanson, MD, Scottsdale

Bruce Dalkin, MD, Tucson

Donald Gleason, MD, Tucson

William Friedel, MD, La Mesa

Stephen Auerbach, MD, Newport Beach

William Moseley, MD, San Diego

Standley Brosman, MD, Santa Monica

Eugene Dula, MD, Van Nuys

B. Thomas Brown, MD, Daytona Beach

Charles Jackson, MD, Fort Lauderdale

Marc Soloway, MD, Miami

Charles Brendler, MD, Chicago

Patrick Guinan, MD, Chicago

Jeffrey Ignatoff, MD, Evanston

David Wood, MD, Lexington

John Tuttle, MD, Lexington

Dennis Venable, MD, Shreveport

Harold Frazier, MD, Bethasda

Myron Murdock, MD, Greenbelt

John Libertino, Burlington

W. Lamar Weems, MD, Jackson

Hugh Fisher, MD, Albany

Michael Blute, MD, Rochester

Michael Wolff, MD, Burlington

Cary Robertson, MD, Durham

Eric Klein, MD, Cleveland

Bruce Lowe, MD, Portland

Jeffrey Cohen, MD, Pittsburgh

Jacques Susset, MD, Providence

L. Dean Knoll, MD, Nashville

Steohen Hardeman, MD, Austin

Ian Thompson, MD, Fort San Houston

Seth Lemer, MD, Houston

Aaron Katz, MD, Richmond

Gary Katz, MD, Richmond

Williams Ellis, MD, Seattle

Richard Boxer, MD, Milwaukee